Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Essilor - News Release: Capital Increase Reserved for Employees

Essilor International
Posted on: 12 Dec 17

Capital Increase Reserved for Employees

PDF Version of the news release

Charenton-le-Pont, France (December 12, 2017 - 6:00 p.m.) - At the Extraordinary General Meeting of May 11, 2017, shareholders of Essilor International (Compagnie Générale d'Optique) ("Essilor") authorized the Board of Directors, within a 26-month period, to issue shares reserved for employees participating in an Essilor employee stock ownership plan, with new shares representing up to 1.5% of the total capital stock (Resolution 18) [1] . The maximum number of common shares previously authorized for issuance was 3,107,595 [2] .
           
At its meeting of December 6, 2017, the Board of Directors decided to issue up to 350,000 common shares reserved for participants in the Essilor / Essilor International [3] / BBGR / Novacel Ophtalmique / BNL Eurolens / Delamare Sovra SAS / Mont Royal / EOMC / DAC Vision / Transitions Optical Distribution Ltd employee stock ownership plans. The new shares will carry dividend rights from January 1, 2017. They will be offered at a price of €85.71 per share, this being the average of the opening prices over the 20 trading days preceding the Board's December 6, 2017 meeting, to which a 20% discount has been applied.

The purpose of this offer is to further involve the Company's employees in its development by allowing them to become shareholders. The shares can be purchased through two funds. These funds have been given a specific value since January 1, 2017, the start date of the subscription period. The closing date of the subscription period was December 11, 2017. The actual number of shares issued will be announced on December 22, 2017, after which the Company will apply for the new shares (par value: €0.18) to be listed on Euronext Paris.

The Company's capital stock amounts to €39,374,683.38, represented by 218,748,241 shares as of November 30, 2017².


About Essilor
Essilor International (Compagnie Générale d'Optique) ("Essilor") is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux ® , Crizal ® , Transitions ® , Eyezen TM , Xperio ® , Foster Grant ® , Bolon TM and Costa ® . It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs approximately 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world (as of December 31, 2016). For more information, please visit www.essilor.com.
The Essilor International share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. 
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

------------------------
Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16


[1] Common ceiling applying to resolutions 18 and 19 adopted by the Extraordinary General Meeting of May 11, 2017

[2] Following the capital increase on November 30, 2017, as authorized by resolution 19 adopted by the Extraordinary General Meeting of May 11, 2017 (see press release issued on November 21, 2017 )

[3] A French simplified joint-stock company (société par actions simplifiée) registered with the Créteil Trade and Companies Register (Registre du Commerce et des Sociétés) under number 439 769 654

PDF Version of the news release


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Essilor International via GlobeNewswire
HUG#2155641
GlobeNewswire
globenewswire.com

Last updated on: 13/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.